Literature DB >> 22697336

Implementation of a lung radiosurgery program: technical considerations and quality assurance in an Australian institution.

Shankar Siva1, Brent Chesson, Yolanda Aarons, Natalie Clements, Tomas Kron, Michael MacManus, David Ball.   

Abstract

INTRODUCTION: The Peter MacCallum Cancer Centre has established a stereotactic lung radiosurgery program for the treatment of isolated lung metastases. The aim of this study was to critically assess the technical feasibility of performing stereotactic lung radiosurgery in an Australian institution.
METHODS: A single 26-Gy fraction of radiotherapy was delivered to patients with positron emission tomography (PET) staged solitary lung metastases. Motion management was addressed using four-dimensional computed tomographic simulation, and cone beam CT (CBCT) online soft-tissue matching. Treatments were with multiple coplanar and non-coplanar asymmetric beams. Patients were immobilised in a dedicated stereotactic body cradle. Quality assurance (QA) of treatment plans with both ion chamber and film measurements was performed accounting for patient-specific respiratory motion.
RESULTS: Between February 2010 and February 2011, nine patients received stereotactic lung radiosurgery. One grade 1 toxicity and one grade 2 toxicity were recorded after treatment. The mean planning target volume was 22.6 cc. A median of eight beams were delivered per treatment plan (range 7-10) with a median of two non-coplanar beams (range 0-6). At treatment plan QA, the difference between planned and delivered dose was ≤1.76% in all static and dynamic ion chamber recordings. A mid-treatment CBCT was performed at a median time of 21 min, with the mean displacement discrepancy from initial set-up being 0.4 mm (range 0-2 mm).
CONCLUSIONS: Stereotactic radiosurgery to the lung was both feasible and tolerable at our institution. Intrafractional immobilisation within 2 mm was reproducible. Excellent concordance between planned and delivered treatments was achieved in the phantom QA.
© 2012 The Authors. Journal of Medical Imaging and Radiation Oncology © 2012 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Mesh:

Year:  2012        PMID: 22697336     DOI: 10.1111/j.1754-9485.2012.02367.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  Loss of Nrf2 accelerates ionizing radiation-induced bone loss by upregulating RANKL.

Authors:  Tapasi Rana; Michelle A Schultz; Michael L Freeman; Swati Biswas
Journal:  Free Radic Biol Med       Date:  2012-10-22       Impact factor: 7.376

2.  An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy.

Authors:  Shankar Siva; Daniel Pham; Suki Gill; Mathias Bressel; Kim Dang; Thomas Devereux; Tomas Kron; Farshad Foroudi
Journal:  Radiat Oncol       Date:  2013-10-26       Impact factor: 3.481

3.  A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II).

Authors:  Shankar Siva; Tomas Kron; Mathias Bressel; Marion Haas; Tao Mai; Shalini Vinod; Giuseppe Sasso; Wenchang Wong; Hien Le; Thomas Eade; Nicholas Hardcastle; Brent Chesson; Daniel Pham; Morten Høyer; Rebecca Montgomery; David Ball
Journal:  BMC Cancer       Date:  2016-03-04       Impact factor: 4.430

4.  Volumetric-modulated Arc Therapy Lung Stereotactic Body Radiation Therapy Dosimetric Quality Assurance: A Comparison between Radiochromic Film and Chamber Array.

Authors:  Juan Fernando Mata Colodro; Alfredo Serna Berná; Vicente Puchades Puchades; David Ramos Amores; Miguel Alcaraz Baños
Journal:  J Med Phys       Date:  2017 Jul-Sep

5.  On the use of a convolution-superposition algorithm for plan checking in lung stereotactic body radiation therapy.

Authors:  Nicholas Hardcastle; Bradley M Oborn; Annette Haworth
Journal:  J Appl Clin Med Phys       Date:  2016-09-08       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.